Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study-Reference-Cited by-同舟云学术

Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study

Published:1992-08 Issue:8 Volume:67 Page:732-738
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

STEADMAN CHARLES J.,TALLEY NICHOLAS J.,PHILLIPS SIDNEY F.,ZINSMEISTER ALAN R.

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. What the gastroenterologist does all day: a survey of a state society's practice;Switz;Gastroenterology,1976

2. Epidemiology of colonic symptoms and the irritable bowel syndrome;Talley;Gastroenterology,1991

3. Controlled treatment trials in the irritable bowel syndrome: a critique;Klein;Gastroenterology,1988

4. Identification of sub-groups of functional gastrointestinal disorders;Drossman;Gastroenterol Int,1990

5. Comparison of rectosigmoid myoelectrical activity in the irritable colon syndrome during relapses and remissions;Taylor;Gut,1978

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diarrhoea of unknown cause: medical treatment in a stepwise manner;Scandinavian Journal of Gastroenterology;2024-02-11

2. Management of Irritable Bowel Syndrome With Diarrhea;Journal of Clinical Gastroenterology;2024-01-15

3. An overview of 5-HT₃ receptor antagonists as a treatment option for irritable bowel syndrome with diarrhea;Expert Opinion on Pharmacotherapy;2023-05-25

4. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility;United European Gastroenterology Journal;2022-06-13

5. Emerging therapies in the management of Irritable Bowel Syndrome (IBS);Expert Opinion on Emerging Drugs;2022-01-02